Brandywine Global Investment Management LLC Sells 1,531 Shares of Halozyme Therapeutics, Inc. $HALO

Brandywine Global Investment Management LLC reduced its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 2.1% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 73,019 shares of the biopharmaceutical company’s stock after selling 1,531 shares during the quarter. Brandywine Global Investment Management LLC owned approximately 0.06% of Halozyme Therapeutics worth $3,798,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in the stock. Alliancebernstein L.P. lifted its holdings in Halozyme Therapeutics by 4.8% during the 1st quarter. Alliancebernstein L.P. now owns 3,215,109 shares of the biopharmaceutical company’s stock valued at $205,156,000 after buying an additional 146,677 shares in the last quarter. Dimensional Fund Advisors LP increased its position in shares of Halozyme Therapeutics by 4.9% during the first quarter. Dimensional Fund Advisors LP now owns 2,029,160 shares of the biopharmaceutical company’s stock worth $129,478,000 after acquiring an additional 95,600 shares during the period. TD Asset Management Inc raised its stake in shares of Halozyme Therapeutics by 5.8% during the first quarter. TD Asset Management Inc now owns 1,451,842 shares of the biopharmaceutical company’s stock valued at $92,642,000 after acquiring an additional 79,708 shares in the last quarter. LSV Asset Management raised its stake in shares of Halozyme Therapeutics by 40.2% during the second quarter. LSV Asset Management now owns 1,255,240 shares of the biopharmaceutical company’s stock valued at $65,298,000 after acquiring an additional 360,049 shares in the last quarter. Finally, Fuller & Thaler Asset Management Inc. boosted its holdings in shares of Halozyme Therapeutics by 27.3% in the first quarter. Fuller & Thaler Asset Management Inc. now owns 1,130,019 shares of the biopharmaceutical company’s stock valued at $72,107,000 after purchasing an additional 242,167 shares during the period. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Insider Buying and Selling

In related news, CFO Nicole Labrosse sold 20,000 shares of the stock in a transaction that occurred on Wednesday, September 10th. The shares were sold at an average price of $75.71, for a total transaction of $1,514,200.00. Following the completion of the sale, the chief financial officer owned 24,306 shares of the company’s stock, valued at $1,840,207.26. This represents a 45.14% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Bernadette Connaughton sold 4,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 2nd. The shares were sold at an average price of $73.68, for a total transaction of $294,720.00. Following the completion of the sale, the director owned 46,952 shares of the company’s stock, valued at approximately $3,459,423.36. This trade represents a 7.85% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 110,227 shares of company stock worth $8,028,955 in the last 90 days. 2.40% of the stock is owned by corporate insiders.

Halozyme Therapeutics Trading Up 2.0%

Shares of NASDAQ HALO opened at $70.34 on Monday. Halozyme Therapeutics, Inc. has a 1-year low of $46.21 and a 1-year high of $79.50. The business has a fifty day moving average price of $69.63 and a 200 day moving average price of $63.50. The stock has a market capitalization of $8.27 billion, a P/E ratio of 16.10, a price-to-earnings-growth ratio of 0.35 and a beta of 1.18. The company has a debt-to-equity ratio of 4.54, a current ratio of 8.36 and a quick ratio of 7.01.

Halozyme Therapeutics (NASDAQ:HALO) last posted its earnings results on Monday, November 3rd. The biopharmaceutical company reported $1.72 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.63 by $0.09. The company had revenue of $354.26 million for the quarter, compared to analyst estimates of $339.18 million. Halozyme Therapeutics had a return on equity of 150.85% and a net margin of 47.28%.The firm’s quarterly revenue was up 22.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.27 earnings per share. Equities research analysts expect that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have commented on HALO. Morgan Stanley reduced their price objective on Halozyme Therapeutics from $80.00 to $79.00 and set an “overweight” rating on the stock in a report on Monday, October 20th. Weiss Ratings restated a “buy (b)” rating on shares of Halozyme Therapeutics in a research note on Wednesday. Benchmark lifted their price objective on Halozyme Therapeutics from $75.00 to $90.00 and gave the company a “buy” rating in a report on Wednesday, September 24th. JMP Securities upped their price objective on shares of Halozyme Therapeutics from $78.00 to $91.00 and gave the stock a “market outperform” rating in a research note on Wednesday, August 6th. Finally, Leerink Partnrs raised shares of Halozyme Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Tuesday, October 14th. Seven investment analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $75.10.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.